Becton Dickinson — Aug 7, 2025 release

Director, Investor Relations - 201-847-6927 Media: Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD Reports Third Quarter Fiscal 2025 Financial Results • Revenue of $5.5 billion increased 10.4% as reported, 8.5% adjusted FXN and 3.0% organic • GAAP and adjusted diluted EPS grew to $2.00 and $3.68, respectively • GAAP and adjusted gross margin up 160 basis points and 50 basis points, respectively, driven by BD Excellence • GAAP and adjusted operating income up 46.6% and 11.3%, respectively • Company raises full-year adjusted diluted EPS guidance to $14.30 to $14.45, reflecting an $0.18 increase to 9.4% growth at the midpoint, while reaffirming organic revenue growth guidance 1 • Expects to complete remaining $250 million of $1 billion share buyback commitment by the end of fiscal 2025 FRANKLIN LAKES, NJ (August 7, 2025) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 third quarter, which ended June 30, 2025. “We increased our organic growth trajectory in Q3 while delivering strong margin and EPS growth fueled by BD Excellence, enabling us to raise our EPS guidance and reaffirm organic revenue growth expectations for the full year,” said Tom Polen, chairman, CEO and president of BD. “We also announced in July an agreement to combine BD’s Biosciences and Diagnostic Solutions business with Waters Corporation, which is expected to create an innovative life science and diagnostic leader focused on high-volume testing with a leading financial outlook. We are focused on closing the transaction and realizing the meaningful value-creation opportunity for BD shareholders through capturing the upside of synergies and growth within the combined company as well as maximizing the value of New BD. Looking ahead for the remaind